LigaChem Biosciences CEO Kim 바카라 카지노: “20 ADC candidates to advance into clinical trials by 2027”

[by Ji, 바카라 카지노 Jun] “We aim to advance a total of 20 antibody-drug conjugate (ADC) assets into clinical trials by 2027.”

Kim 바카라 카지노, CEO of LigaChem Biosciences (hereinafter referred to as LCB), made this announcement during the ‘LigaChemBio Global R&D DAY 2025’ held on July 1 in Yeouido, Seoul. “We currently have five ADC assets in clinical trials,” he further commented. “We are aggressively expanding our pipeline to ensure that an additional 15 ADC candidates enter clinical trials by 2027.”

Building upon its existing portfolio of ADCs utilizing small molecule compounds, LCB plans to advance the development of next-generation modalities, including ‘dual antibody ADCs,’ ‘immunomodulatory antibody conjugates (AICs),’ and ‘dual payload ADCs.’ The company also intends to explore the therapeutic potential of ‘peptide drug conjugates (PDCs).’ “Several of the ADC candidates currently under development incorporate a significant portion of novel targets,” Kim noted.

LCB is also actively pursuing the development of novel payloads, with the objective of addressing resistance issues associated with currently used payloads in ADCs. At present, ADC payloads are broadly categorized into two groups: those with high cytotoxicity, such as the ‘MMAE,’ ‘DM1,’ and ‘PBD’ series, and those with relatively low toxicity, such as the ‘Topo1’ series.

LCB introduced a series of new payload candidates, including TOPOi (non-camptothecins), immuno-oncology STING agonists (I-O STING), TLR7/8 agonists, novel payloads, and targeted protein degraders (TPD). “Identifying new payloads is a difficult task, but it is absolutely necessary,” Kim stated. “We intend to develop new payloads through open innovation in collaboration with external partners, rather than relying solely on internal development,” he added.